ALK 酪氨酸激酶抑制剂治疗后发现 BRAF V600E 突变的年轻成人患 HIP1-ALK 重排肺癌：病例报告

IF 3 Q2 ONCOLOGY

JTO Clinical and Research Reports Pub Date : 2023-11-25 DOI:10.1016/j.jtocrr.2023.100612

Aiko Ogimoto MD, Naoko Katsurada MD, PhD, Atsuhiko Yatani MD, Chihiro Mimura MD, Masatsugu Yamamoto MD, PhD, Motoko Tachihara MD, PhD

{"title":"ALK 酪氨酸激酶抑制剂治疗后发现 BRAF V600E 突变的年轻成人患 HIP1-ALK 重排肺癌：病例报告","authors":"Aiko Ogimoto MD, Naoko Katsurada MD, PhD, Atsuhiko Yatani MD, Chihiro Mimura MD, Masatsugu Yamamoto MD, PhD, Motoko Tachihara MD, PhD","doi":"10.1016/j.jtocrr.2023.100612","DOIUrl":null,"url":null,"abstract":"<div><p>HIP1-ALK is a relatively rare fusion pattern in ALK-rearranged NSCLC. Existing studies on the efficacy of ALK tyrosine kinase inhibitor (TKI) resistance mechanisms and treatment strategies in HIP1-ALK–rearranged lung cancer are limited. Here, we report the case of an 18-year-old man with HIP1-ALK–rearranged adenocarcinoma who developed BRAF V600E and V1180L mutations after ALK TKI therapy, in whom the administration of BRAF and MEK inhibitors was ineffective. Brigatinib was effective after chemotherapy with cytotoxic drugs. Development of effective treatments is desirable for rare variants of ALK-rearranged lung cancer after acquiring resistance to ALK TKIs.</p></div>","PeriodicalId":17675,"journal":{"name":"JTO Clinical and Research Reports","volume":null,"pages":null},"PeriodicalIF":3.0000,"publicationDate":"2023-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666364323001558/pdfft?md5=a6b0f6966969f24e8a5f368b3ea208c7&pid=1-s2.0-S2666364323001558-main.pdf","citationCount":"0","resultStr":"{\"title\":\"HIP1-ALK–Rearranged Lung Cancer in a Young Adult With BRAF V600E Mutation Detected After ALK Tyrosine Kinase Inhibitor Therapy: A Case Report\",\"authors\":\"Aiko Ogimoto MD, Naoko Katsurada MD, PhD, Atsuhiko Yatani MD, Chihiro Mimura MD, Masatsugu Yamamoto MD, PhD, Motoko Tachihara MD, PhD\",\"doi\":\"10.1016/j.jtocrr.2023.100612\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>HIP1-ALK is a relatively rare fusion pattern in ALK-rearranged NSCLC. Existing studies on the efficacy of ALK tyrosine kinase inhibitor (TKI) resistance mechanisms and treatment strategies in HIP1-ALK–rearranged lung cancer are limited. Here, we report the case of an 18-year-old man with HIP1-ALK–rearranged adenocarcinoma who developed BRAF V600E and V1180L mutations after ALK TKI therapy, in whom the administration of BRAF and MEK inhibitors was ineffective. Brigatinib was effective after chemotherapy with cytotoxic drugs. Development of effective treatments is desirable for rare variants of ALK-rearranged lung cancer after acquiring resistance to ALK TKIs.</p></div>\",\"PeriodicalId\":17675,\"journal\":{\"name\":\"JTO Clinical and Research Reports\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":3.0000,\"publicationDate\":\"2023-11-25\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S2666364323001558/pdfft?md5=a6b0f6966969f24e8a5f368b3ea208c7&pid=1-s2.0-S2666364323001558-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"JTO Clinical and Research Reports\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2666364323001558\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"JTO Clinical and Research Reports","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2666364323001558","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

HIP1-ALK是ALK重排NSCLC中相对罕见的融合模式。关于ALK酪氨酸激酶抑制剂（TKI）在HIP1-ALK重排肺癌中的耐药机制和治疗策略的现有研究非常有限。在此，我们报告了一例患有 HIP1-ALK 重排腺癌的 18 岁男性患者，他在接受 ALK TKI 治疗后发生了 BRAF V600E 和 V1180L 突变，而 BRAF 和 MEK 抑制剂对其无效。在使用细胞毒性药物化疗后，布加替尼对其有效。对于ALK TKIs耐药后的ALK重排肺癌罕见变种，开发有效的治疗方法是可取的。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

HIP1-ALK–Rearranged Lung Cancer in a Young Adult With BRAF V600E Mutation Detected After ALK Tyrosine Kinase Inhibitor Therapy: A Case Report

HIP1-ALK is a relatively rare fusion pattern in ALK-rearranged NSCLC. Existing studies on the efficacy of ALK tyrosine kinase inhibitor (TKI) resistance mechanisms and treatment strategies in HIP1-ALK–rearranged lung cancer are limited. Here, we report the case of an 18-year-old man with HIP1-ALK–rearranged adenocarcinoma who developed BRAF V600E and V1180L mutations after ALK TKI therapy, in whom the administration of BRAF and MEK inhibitors was ineffective. Brigatinib was effective after chemotherapy with cytotoxic drugs. Development of effective treatments is desirable for rare variants of ALK-rearranged lung cancer after acquiring resistance to ALK TKIs.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

JTO Clinical and Research Reports Medicine-Oncology

CiteScore

4.20

自引率

0.00%

发文量

145

审稿时长

19 weeks